CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 149 enrolled
Drug / intervention
Docetaxel +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00880334
NCT00880334Phase 2Completed
CompareCT.gov

Randomized Study of Docetaxel +/- Vandetanib in Metastatic TCC

Dana-Farber Cancer Institute·interventional·Posted Apr 13, 2009·Updated Sep 18, 2018

In Brief

A Phase 2 clinical trial evaluating Docetaxel, vandetanib, and 1 other intervention for Transitional Cell Carcinoma and Bladder Cancer. Completed, enrolled 149 participants across 3 sites.

Detailed Summary

In this research study the investigators are looking to see if the combination of docetaxel plus Vandetanib is effective in the treatment of metastatic transitional cell carcinoma (TCC). Docetaxel is a chemotherapy drug that kills cancer cells that are dividing. It is widely used in TCC. Vandetanib is a drug that is believed to stop new blood vessels from forming around cancer cells. The combination of docetaxel and Vandetanib has been studied in people with lung cancer and found to be helpful in killing cancer cells. Thus, this study is looking at people with TCC, to see if the combination of docetaxel plus Vandetanib is better or worse then docetaxel alone.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsTransitional Cell Carcinoma, Bladder Cancer
CountriesUnited States
CollaboratorsBrigham and Women's Hospital, Beth Israel Deaconess Medical Center, Massachusetts General Hospital, AstraZeneca

Timeline

Phase 2CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedApr 13, 2009
Enrollment StartSep 1, 2006
Primary CompletionDec 1, 2013
Study CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 7.3 yearsPosted 17.2 years ago

Interventions

Docetaxeldrug

Given intravenously on Day 1 of each 21-day cycle

vandetanibdrug

taken orally once a day, every day

Placebodrug

Taken orally once a day every day